The settlement between researcher Renee Kaswan and the foundation ends a seven-year dispute over a drug called Restasis, which alleviates chronically dry eyes.
Allergan, a pharaceutical company, bought the right to develop and market the drug from the research foundation in the 1990s. Kaswan said UGA lost more than $200 million in fees in 2003 by negotiating a new deal for the drug without her knowledge.
Under the settlement, Kaswan agrees to release the drug company and the research foundation from future claims.
Post a Comment